

# Bruno Pradines, PharmD, PhD

---



## Professional Background

---

Bruno Pradines underwent pharmaceutical industry training at the Faculty of Pharmacy of Limoges, and then scientific and medical training in microbiology and infectious diseases at the Montpellier University and the Marseille Medical School. He worked one year in pharmaceutical laboratory. Then in 1994, he joined the Tropical Medicine Institute of the Health Service of the French Army (IMTSSA, Le Pharo, Marseille, France). He is now the chief of the Unit of Parasitology and Entomology of the Biomedical Research Institute of the French Army (IRBA, Marseille, France) and the leader of the Malaria and Vectors team in the Research Unit VITROME (IHU Méditerranée Infection).

## Research

---

The main thematics developed by B Pradines are focused on malaria, and especially on malaria drugs: surveillance of *Plasmodium falciparum* susceptibility to antimalarial drugs, identification of new molecular markers of resistance, screening of new antimalarial drugs, knowledge on mode of action and mechanism of resistance to antimalarial drugs. Leader on ex vivo and in vitro malaria testing, the B Pradines is one of the coordinators of the National Centre of Malaria Reference (CNR paludisme). He manages several research programs in Senegal, Djibouti, Gabon, Republic of Congo, Comoros and created in 2009 a malaria chemosusceptibility laboratory in the Senegalese Military Hospital in Dakar, Senegal (Hôpital Principal de Dakar). He is co-author of more than a 200 publications on malaria.

## Awards



---

Bruno Pradines has received several prizes and awards including the French Academy of Pharmacy award and the Val-de-Grace School prize.

# Publications

## Total Publications

220



- Malvy D, Torrentino-Madamet M, L'ollivier C, Receveur MC, Jeddi F, Delhaes L, Piarroux R, Millet P, **Pradines B**. Plasmodium falciparum recrudescence two years after a first treated uncomplicated infection without return in a malaria endemic area. Antimicrob Agents Chemother., 2017, in press.
- Gendrot M, Diawara S, Madamet M, Kounta Mb, Briolant S, Wade Ka, Fall M, Benoit N, Nakoulima N, Amalvict R, Diémé Y, Fall B, Wade B, Diatta B, **Pradines B**. Association between polymorphisms in the pfmdr6 gene and ex vivo susceptibility to quinine in Plasmodium falciparum parasites from Dakar, Senegal. Antimicrob Agents Chemother., 2017, 61:e01183-16.
- Madamet M, Kouta MB, Wade KA, Lo G, Diawara S, Fall M, Bercion R, Nakoulima A, Fall KB, Benoit N, Gueye MW, Fall B, Diatta B, **Pradines B**. Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after the treatment with artemisinin derivatives in Senegal. Int J Antimicrob Agents, 2017, 49:754-756.
- Diawara S, Madamet M, Kounta MB, Lo G, Wade KA, Nakoulima A, Bercion R, Amalvict R, Gueye MW, Fall B, Diatta B, **Pradines B**. Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015. Malar J., 2017, 16:118.
- Ould Ahmadou Salem MS, Mint Lekweiry K, Bouchiba H, Pascual A, **Pradines B**, Ould Mohamed Salem Boukhaey A, Briolant S, Basco LK, Bogreau H. Characterization of Plasmodium falciparum genes associated with drug resistance in Hodh Eigharbi, a malaria hotspot near Malian-Mauritanian border. Malar J., 2017, 16:140.
- Gaillard T, Briolant S, Madamet M, **Pradines B**. The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malar J., 2017, 16:148.
- Fall B, Madamet M, Diawara S, Briolant S, Wade KA, Lo G, Nakoulima A, Fall M, Bercion R, Kounta MB, Amalvict R, Benoit N, Gueye MW, Diatta B, Wade B, **Pradines B**. Ex vivo activity of Proveblue, a methylene blue, against field isolates of Plasmodium falciparum in Dakar, Senegal from 2013-2015. Int J Antimicrob Agents, 2017, 50:155-158.
- Le PM, Srivastava V, Nguyen TT, **Pradines B**, Madamet M, Mosnier J, Trinh TT, Lee H. Stephanine from Stephania venosa (blume) spreng showed effective antiplasmodial and anticancer activities, the latter by inducing apoptosis through the reverse of mitotic exit. Phytother Res., 2017, 31:1357-1368.
- Laroche M, Béranger Jm, Delauney P, Charrel R, **Pradines B**, Berger F, Ranque S, Bitam I, Davoust B, Raoult D, Parola P. Medical entomology. A reemerging field of research to better understand vector-borne infectious diseases. Clin Infect Dis., 2017, 65(suppl\_1):S30-S38.

10. Briolant S, **Pradines B**, Basco Lk. Rôle de la primaquine dans le contrôle et l'élimination du paludisme en Afrique francophone. *Bull Soc Pathol Exot.*, 2017, 110 :198-206.
11. Boussaroque A, Fall B, Madamet M, Camara C, Benoit N, Fall M, Nakoulima A, Dionne P, Ba Fall K, Diatta B, Diémé Y, Wade B, **Pradines B**. Emergence of mutations in the K13 Propeller gene of *Plasmodium falciparum* isolates from Dakar, Senegal in 2013-2014. *Antimicrob. Agents Chemother.* 2016, 60, 60:624-627.
12. Singana BP, Bogreau H, Matondo BD, Dossou-Yavo LR, Casimiro PN, Mbouka R, Yen HA Nguyen K, **Pradines B**, Basco LK, Ndounga M. Malaria prevalence and antimalarial drug efficacy in Owando, northern Congo. *Malar. J.*, 2016, 15:16.
13. Gaillard T, Dormoi J, Madamet M, **Pradines B**. Macrolides in malaria. *Malar. J.*, 2016, 15:85.
14. Madamet M, Briolant S, Amalvict R, Benoit N, Bouchiba H, Cren J, **Pradines B**. The *Plasmodium falciparum* chloroquine resistance transporter is associated with ex vivo *P. falciparum* parasite response to pyronaridine. *Parasit Vect.*, 2016, 9:77.
15. Créach MA, Velut G, Berger F, De Laval F, Briolant S, Aigle L, Marimoutou C, Nivoix P, Meynard JB, **Pradines B**, Simon F, Michel R, Mayet A. Factors associated with malaria chemoprophylaxis compliance among French service members deployed in Central African Republic. *Malar. J.*, 2016, 15:174.
16. Javelle E, Madamet M, Gaillard T, Velut G, Surcouf C, Michel R, Garnotel E, Simon F, **Pradines B**. Delayed *P. falciparum* malaria after doxycycline prophylaxis, Central African Republic. *Antimicrob. Agents Chemother.*, 2016, 60:2592-2593.
17. Fall B, Madamet M, Camara C, Amalvict R, Fall M, Nakoulima A, Diatta B, Diémé Y, Wade B, **Pradines B**. Emergence of *Plasmodium falciparum* in vitro resistance to monodesethylamodiaquine in Dakar, Senegal in 2014. *Emerg. Infect. Dis.*, 2016, 22:841-845.
18. Menard D, Khim N, Beghain J, Adegnika AA, Alam MS, Amodu O, Awab Gr, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Das Thakur G, Dieye A, Djalle D, Dorkenoo MA, Eboumbou Moukoko CE, Espino E, Fandeur T, Ferreira-Da-Cruz Mf, Fola AA, Fuehrer HP, Hassan Am, Herrera S, Hongvanthong B, Houze S, Karim MJ, Jiang L, Kano S, Khan WA, Khanthavong M, Kreamsner PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Laminou IM, Mazarati JB, Menard S, Morlais I, Muhindo Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niare K, Noeldi H, Ouedraogo JB, Pillai DR, **Pradines B**, Quang Phuc B, Ramharther M, Randrianarivelojosa M, Sattabongkot J, Sheikh Omar R, Silue KD, Sirima SB, Sutherland C, Syafrudin D, Tahar R, Tang LH, Toure OA, Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, Witkowski B, Fidock DA, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O; for the K13 Artemisinin Resistance Multicenter Assessment consortium (KARMA). A worldwide map of *Plasmodium falciparum* artemisinin resistance. *N. Engl. J. Med.*, 2016, 374:2453-2464.
19. Gendrot M, Fall B, Madamet M, Fall M, Wade KA, Amalvict R, Nakoulima A, Benoit N, Diawara S, Diémé Y, Diatta B, Wade B, **Pradines B**. Absence of association between polymorphisms in the RING E3 ubiquitin-protein ligase gene and ex vivo susceptibility to conventional antimalarial drugs in *Plasmodium falciparum* isolates from Dakar, Senegal. *Antimicrob. Agents Chemother.*, 2016, 60:5010-5013.
20. Ehrhardt K, Deregnacourt C, Goetz Aa, Tzanova T, Gallo V, Arese P, **Pradines B**, Adjalley Sh, Bagrel D, Blandin S, Lanzer M, Davioud-Charvet E. The Redox Cycler Plasmodione is a fast-acting antimalarial lead compound with pronounced activity against sexual and early asexual blood-stage parasites. *Antimicrob Agents Chemother.*, 2016, 60:5146-58.
21. Boussaroque A, Fall B, Madamet M, Wade KA, Fall M, Nakoulima A, Fall KB, Dionne P, Benoit N, Diatta B, Diémé Y, Wade B, **Pradines B**. Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. *Malar. J.*, 2016, 15:347.
22. Roseau JB, **Pradines B**, Paleiron N, Vedy S, Madamet M, Simon F, Javelle E. Failure of dihydroartemisinin plus piperaquine treatment of *falciparum* malaria by under-dosing in an overweight patient. *Malar. J.*, 2016, 15:479.
23. Gaillard T, Madamet M, Tsombeng Ff, Dormoi J, **Pradines B**. Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? *Malar. J.*, 2016, 15:556.
24. Fall B., Camara C., Fall M., Nakoulima A., Dionne P., Diatta B., Dieme Y., Wade B., **Pradines B**. *Plasmodium falciparum* susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the malaria season 2013-2014. *Malar. J.*, 2015, 14:60.

25. Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, Travers D, **Pradines B** and the French National Reference Centre for Imported Malaria Study Group. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperazine and pyronaridine. *Malar. J.*, 2015, 14 :49.
26. Gaillard T, Sriprawat K, Briolant S, Wangsing C, Wurtz N, Baragatti M, Lavina M, Pascual A, Nosten F, **Pradines B**. Molecular markers and in vitro susceptibility to doxycycline in Plasmodium falciparum isolates from Thailand. *Antimicrob. Agents Chemother.*, 2015, 59:5080-5083.
27. Madamet M, Gaillard T, Velut G, Ficko C, Houze P, Bylicki C, Merat S, Houze S, Taudon N, Michel R, Pasquier P, Rapp C, **Pradines B**. Malaria prophylaxis failure with doxycycline, Central African Republic, 2014. *Emerg. Infect. Dis.*, 2015, 21:1485-1486.
28. Gaillard T, Wurtz N, Houze S, Sriprawat K, Wangsing C, Hubert V, Lebras J, Nosten F, Briolant S, **Pradines B**. Absence of association between Plasmodium falciparum small subunit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline. *Malar. J.*, 2015, 14:348.
29. Torrentino-Madamet M, Collet L, Lepère J F, Benoit N, Amalvict R, Ménard D, **Pradines B**. K13-propeller polymorphisms in Plasmodium falciparum isolated in Mayotte in 2013. *Antimicrob Agents Chemother.*, 2015, 59:7878-7880.
30. Gaillard T, Madamet M, **Pradines B**. Tetracyclines in malaria. *Malar J.*, 2015, 14:445.
31. Ibrahim N, Ibrahim H, Dormoi J, Briolant S, **Pradines B**, Moreno A, Mazier D, Legrand P, Nepveu F. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy. *Int J Pharm.*, 2014, 464:214-224.
32. Dormoi J, Savini H, Amalvict R, Baret E, **Pradines B**. In vitro interaction of lumefantrine and piperazine by atorvastatin against Plasmodium falciparum. *Malar J.*, 2014, 13:189.
33. Kumar K, **Pradines B**, Madamet M, Amalvict R, Kumar V. 1H-1,2,3-triazole tethered mono- and bis-ferrocenyl-chalcone-b-lactam conjugates: synthesis and antimalarial evaluation. *Eur J Med Chem.*, 2014, 86:113-212.
34. Migliani R, **Pradines B**, Michel R, Aoun O, Dia A, Deparis X, Rapp C. Malaria control strategies in French armed forces. *Trav Med Infect Dis.*, 2014, 13:307-317.
35. Wurtz N, Fall B, Pascual A, Fall M, Baret E, Camara C, Nakoulima A, Diatta B, Ba Fall K, Mbaye PS, Dieme Y, Bercion R, Wade B, **Pradines B**. Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine and dihydroartemisinin. *Antimicrob Agents Chemother.*, 2014, 58:7032-7040.
36. Kumar K, **Pradines B**, Madamet M, Amalvict R, Benoit N, Kumar V. 1H-1,2,3-triazole tethered isatin-ferrocene conjugates: Synthesis and in vitro antimalarial evaluation. *Eur. J. Med. Chem.*, 2014, 87:801-804.
37. Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall M, Dionne P, Fall Ba K, Nakoulima A, Diatta B, Dieme Y, Menard D, Wade B, **Pradines B**. Limited polymorphisms in K13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013. *Malar J.*, 2014, 13:472.
38. Navarro M, Castro W, Madamet M, Amalvict R, Benoit N, **Pradines B**. Metal-chloroquine derivatives as possible anti-malarial drugs: evaluation of anti-malarial activity and mode of action. *Malar J.*, 2014, 13:471.
39. Arabicia R, Biot C, Delanet G, Roussel P, Pascual A, **Pradines B**, Klahn H. Cyrehetrenyl chalcones : Synthesis, characterisation and antimalarial evaluation. *J Organomet Chem.*, 2013, 723,143-148.
40. Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, Diatta B, Ba Fall K, Saliou Mbaye P, Diémé Y, Bercion R, Wade B, Briolant S, **Pradines B**. Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: Impact on rapid malaria diagnostic tests. *Malar J.*, 2013, 12, 34.
41. Fall B, Pascual A, Sarr FD, Wurtz N, Richard V, Baret E, Dieme Y, Briolant S, Bercion R, Wade B, Tall A, **Pradines B**. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. *Malar J.*, 2013, 12, 107.
42. Pascual A, Fall B, Wurtz N, Fall M, Camara C, Nakoulima A, Baret E, Diatta B, Wade B, Briolant S, **Pradines B**. Plasmodium falciparum with multidrug resistance 1 gene duplications, Senegal. *Emerg Infect Dis.*, 2013, 19, 814-815.
43. Dormoi J., Briolant S., Desgrouas C., **Pradines B**. Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. *Malar J.*, 2013, 12, 127.
44. Gharbi M, Flegg Ja, Hubert V, Kendjo E, Metcalf Je, Bertaux L, Guérin Pj, Le Bras J; Members Of The French National Reference Centre For Imported Malaria Study, Aboubaca A, Agnamey P, Angoulvant A, Barbut P, Basset D, Belkadi G, Bellanger Ap, Bemba D, Benoit-Vica F, Berry A, Bigel MI, Bonhomme J, Botterel F, Bouchaud O, Bougnoux Me, Bourrée P, Bourgeois N, Branger C, Bret L, Buret B, Casalino E, Chevrier S, Conquere De Monbrison F, Cuisenier B, Danis M, Darde MI, De Gentile L, Delarbre Jm, Delaunay P, Delaval A, Desoubeaux G, Develoux M, Dunand J, Durand R, Eloy O, Fauchet N, Faugere B, Faye A, Fenneteau O, Flori P, Fontrouge M, Garabedian C, Gayandrieu F, Godineau N, Houzé P, Houzé S, Hurst Jp, Ichou H, Lachaud L, Lebuissou A, Lefevre M, Leguern As, Le Moal G, Lusina D, Machouart Mc, Malvy D, Matheron S, Maubon D, Mechali D, Megarbane B, Menard G, Millon L, Aiach Mm, Minodier P, Morelle C, Nevez G, Parola P, Parzy D, Patey O, Patoz P, Penn P, Perignon A, Picot S, Pilo Je, Poilane I, Pons D, Poupart M, **Pradines B**, Raffenot D, Rapp C, Receveur Mc, Sarfati C, Senghor Y, Simon F, Siriez Jy, Taudon N, Thellier M, Thouvenin M, Toubas D. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. *Malar J.*, 2013, 12, 35.

45. Pascual A, Fall B, Wurtz N, Fall M, Camara A, Baret E, Diatta B, Ba Fall K, Mbaye PS, Dieme Y, Bercion R, Bogreau H, Briolant S, Rogier C, Wade B, **Pradines B**. In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na<sup>+</sup>/H<sup>+</sup> exchanger transporter (Pfnhe-1) gene in 393 isolates from Dakar, Senegal. *Malar J.*, 2013, 12, 189.
46. Dormoi J, Briolant S, Desgrouas C, **Pradines B**. Efficacy of Proveblue<sup>®</sup>, Methylene Blue, in an Experimental Cerebral Malaria Murine Model. *Antimicrob Agents Chemother.*, 2013, 57, 3412-3414.
47. Dormoi J, **Pradines B**. Dose responses of Proveblue Methylene Blue in an experimental murine cerebral malaria model. *Antimicrob Agents Chemother.*, 2013, 57, 4080-4081.
48. Abdi Khaireh B, Assefa A, Hassan Guessod H, Basco LK, Abdi Khaireh M, Pascual A, Briolant S, Mohamed Bouh S, Hassan Farah I, Moussa Ali H, Ahmed Abdi A, Osman Aden M, Abdillahi Z, Nour Ayeh S, Youssouf Darar H, Koeck J-L, Rogier C, **Pradines B**, Bogreau H. Population genetics analysis during elimination process of Plasmodium falciparum in Djibouti. *Malar J.*, 2013, 12, 201.
49. Woodrow C, Dahlström S, Cooksey R, Flegg JA, Le Nagard H, Mentre F, Murillo C, Menard D, Nosten F, Sriprawatt K, Musset L, Quashie NB, Lim P, Fairhurst RM, Nsohya SL, Sinou V, Noedl H, **Pradines B**, Johnson JD, Guerin PJ, Sibley C, Le Bras J. High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. *Antimicrob Agents Chemother.*, 2013, 57, 3121-3130.
50. Toro P, Klahn H, **Pradines B**, Lahoz F, Pascual A, Biot C, Arancibia R. Organometallic benzimidazoles: Synthesis, characterization and antimalarial activity. *Inorg Chem Com.*, 2013, 35, 126-129.
51. Dormoi J, Briolant S, Pascual A, Desgrouas C, Travaille C, **Pradines B**. Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. *Malar J.*, 2013, 12:302.
52. Gaillard T, Briolant S, Houze S, Baragatti M, Wurtz N, Hubert V, Lavina M, Pascual A, Travaille C, Le Bras J, **Pradines B**. PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. *Malar J.*, 2013, 12:414.
53. Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, Cren J, Taudon N, Rogier C, Parzy D, **Pradines B**. In vitro piperazine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. *Malar J.*, 2013, 12:431.
54. Gharbi M, Flegg JA, **Pradines B**, Berenger A, Ndiaye M, Djimde AA, Roper C, Hubert V, Kendjo E, Venkatesan M, Basseur P, Gaye O, Offianan AT, Penali L, Le Bras J, Guerin PJ. Surveillance of travellers: An additional tool for tracking antimalarial drug resistance in endemic countries. *PlosOne*, 2013, 8, 77775.
55. Wurtz N, Briolant S, Lemarie' D, Pommier De Santi V, Pascual A, Roodt T, Benoit N, Hupin C, **Pradines B**. Retard de diagnostic d'un accès palustre à Plasmodium falciparum chez un militaire en Ouganda : négativité des tests de diagnostic rapide associée à un polymorphisme de l'antigène HRP2. *Med Sante Trop.*, 2013, 23, 181-184.
56. Mint Lekweiry K, Mohamed Salem Boukhary AO, Gaillard T, Wurtz N, Bogreau H, Haffid JE, Trape JF, Bouchiba H, Ahmedou Salem MSO., **Pradines B**, Rogier C, Basco LK, Briolant S. Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps, and pvmdr1 markers in Nouakchott, Mauritania. *J Antimicrob Chemother.*, 2012, 67, 367-374.
57. Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, Baret E, Amalvict R, Soulard R, Rogier C, **Pradines B**. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. *Malar J.*, 2012, 11, 13.
58. Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, Delaunay P, Basset D, Maubon D, Faugere B, Menard G, Bourgeois N, Oeuvray C, Didillon E, Rogier C, **Pradines B**. Ex vivo activity of the ACT new compounds pyronaridine and piperazine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. *Malar J.*, 2012, 11, 45.
59. Briolant S, Bogreau H, Gil M, Bouchiba H, Baret E, Amalvict R, Rogier C, **Pradines B**. F423Y mutation in the pfmdr2 gene and the triple mutation (N51I, C59R, S108N) in pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates. *Antimicrob Agents Chemother.*, 2012, 56, 2750-2752.
60. Dormoi J, Pascual A, Briolant S, Amalvict R, Charras S, Baret E, Huyghues Des Etages E, Feraud M, **Pradines B**. Proveblue (Methylene Blue): In Vitro Synergy in Combinational Therapy with Dihydroartemisinin. *Antimicrob Agents Chemother.*, 2012, 56, 3467-3469.
61. Yu XM, Ramiandrasoa F, Guetzoyan L, **Pradines B**, Quintino E, Gabelle D, Forterre P, Cresteil T, Mahy JP, Pethe S. Synthesis and biological evaluation of acridine derivatives as antimalarial agents. *ChemMedChem*, 2012, 7, 587-605.
62. Gaillard T, Fall B, Tall A, Wurtz N, Diatta B, Lavina M, Ba Fall K, Diene Sarr F, Baret E, Diémé Y, Wade B, Bercion R, Briolant S, **Pradines B**. Absence of association between ex vivo susceptibility to doxycycline and pftetQ and pfmdt copy numbers in Plasmodium falciparum isolates from Dakar, Senegal. *Clin Microbiol Infect.*, 2012, 18, E238-E240.
63. Wurtz N, Pascual A, Marin-Jauffre A, Bouchiba H, Benoit N, Desbordes M, Martelloni M, Pommier De Santi V, Richa G, Taudon N, **Pradines B**, Briolant S. Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast. *Malar J.*, 2012, 11, 146.
64. Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Dieme Y, Rogier C, Bercion R, Briolant S, Wade B, **Pradines B**. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. *Malar J.*, 2012, 11, 197.



65. Gharbi M, Pillai DR, Lau R, Hubert V, Khaimar K, Existe A, Kendjo A, Dahlstrom S, Guérin PJ, Le Bras J, Members of the French National Reference Center for Imported Malaria Study. Chloroquine-resistance malaria in travellers returning from Haiti after 2010 earthquake. *Emerg Infect Dis.*, 2012, 18, 1346-1349.
66. Quirante J, Dubar F, Gonzalez A, Lopez C, Cascante M, Cortes R, Forfar I, **Pradines B**, Biot C. Ferrocene-indole hybrids for cancer and malaria therapy. *J Org Chem.*, 2011; 696, 1011-1017.
67. Dubar F, Egan TJ, **Pradines B**, Kuter D, Ncokazi KK, Forge D, Pal JF, Pierrot C, Kalamou H, Khalife J, Buisine E, Rogier C, Vezin H, Forfar I, Slomianny C, Trivelli X, Kaoishnikov S, Leiserowitz L, Dive D, Biot C. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. *ACS Chem Biol.* 2011; 6, 275-287.
68. Bertaux L, Kraemer P, Taudon N, Trignol A, Martelloni M, Saidi R, Parzy D, **Pradines B**, Simon F. Quinine-Resistant Malaria in Traveller Returning from French Guiana, 2010. *Emerg Infect Dis.*, 2011, 17, 943-945.
69. Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, **Pradines B**. Use of the atmospheric generators for capnophilic bacteria Genbag CO2® for the evaluation of in vitro Plasmodium falciparum susceptibility to standard antimalarial drugs. *Malar J.*, 2011, 10, 8.
70. Briolant S, Pelleau S, Bogreau H, Hovette P, Zettor A, Castello J, Baret E, Amalvict R, Rogier C, **Pradines B**. In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na<sup>+</sup>/H<sup>+</sup> exchanger (Pfnhe-1) gene: The absence of association in clinical isolates from the Republic of Congo. *Malar J.*, 2011, 10, 37.
71. Dubar F, Wintjens R, Martins-Duarte ES, Vommaro RC, Souza W, Dive D, Pierrot C, **Pradines B**, Wohlkonig A, Khalife J, Biot C. Ester prodrugs of ciprofloxacin as DNA-gyrase inhibitors: synthesis, antiparasitic evaluation and docking studies. *Med Chem Commun.*, 2011, 2, 430-435.
72. Pascual A, Henry M, Briolant S, Charras S, Baret E, Amalvict R, Huyghues Des Etages E, Feraud M, Rogier C, **Pradines B**. In Vitro Activity of Proveblue™ (Methylene Blue) on Plasmodium falciparum Strains Resistant to Standard Antimalarial Drugs. *Antimicrob Agents Chemother.*, 2011, 55, 2472-2474.
73. Deplaine G, Lavazec C, Bischoff E, Natalang O, Perrot S, Guillotte-Blisnick M, Coppee JY, **Pradines B**, Mercereau-Puijalon O, David PH. Artesunate tolerance in transgenic Plasmodium falciparum parasites over-expressing a tryptophan rich protein. *Antimicrob Agents Chemother.*, 2011, 55, 2576-2584.
74. Sagui E, Resseguier N, Machault V, Ollivier L, Orlandi-Pradines E, Texier G, Pages F, Michel R, **Pradines B**, Briolant S, Buguet A, Tourette-Turgis C, Rogier C. Determinants of compliance with anti-vectorial protective measures among non-immune travellers during missions to tropical Africa. *Malar J.*, 2011, 10, 232.
75. **Pradines B**, Bertaux B, Pomares C, Delaunay P, Marty P. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. *Malar J.*, 2011, 10, 268.
76. Mint Lekweiry K, Basco LK, Ahmedou Salem MSO, Haffid JE, Marin-Jauffre A, Weddih AO, Briolant S, Bogreau H, **Pradines B**, Rogier C, Trape JF., Mohamed Salem Boukhary AO. Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. *Trans R Soc Trop Med Hyg.*, 2011, 105, 727-733.
77. Fall B, Diawara S, Sow K, Baret E, Diatta B, Ba Fall K, Mbaye PS, Fall F, Diémé Y, Rogier R, Wade B, Bercion R, **Pradines B**. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. *Malar J.*, 2011, 10, 310.
78. Pelleau S, Bertaux L, Briolant S, Ferdig MT, Sinou V, **Pradines B**, Parzy D, Jambou R. Differential association of Plasmodium falciparum Na<sup>+</sup>/H<sup>+</sup> exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum. *Antimicrob Agents Chemother.*, 2011, 55, 5834-5841.
79. Andriantsoanirina V, Durand R, **Pradines B**, Baret E, Bouchier C, Ratsimbaoa A, Menard D. In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum. *Malar J.*, 2011, 10, 283.
80. Wurtz N, Mint Lekweiry K, Bogreau H, **Pradines B**, Rogier C, Salem Boukhary AO, Hafid JE, Ahmedou Salem MS, Trape JF, Basco LK, Briolant S. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. *Malar J.*, 2011, 10, 336.
81. Quirante J, Ruiz D, Gonzalez A, Lopez C, Cascante M, Cortes R, Messeguer R, Calvis C, Bamdoma L, Pascual A, Guerardel Y, **Pradines B**, Font-Bardia M, Calvet T, Biot C. Platinum (II) and Palladium (II) complexes with (N,N') and (C,N,N') ligands derived from pyrazole as anticancer and antimalarial agents : synthesis, characterization and in vitro activities. *J Inorg Biochem.*, 2011, 105, 1720-1728.
82. Rapp C, Simon F, **Pradines B**. Prévention du paludisme d'importation en France métropolitaine. *Actualité et Dossier en Santé Publique*, 2011, 76, 36-39.
83. Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, **Pradines B**. Atorvastatin as a potential antimalarial drug: In vitro synergy in combinational therapy with dihydroartemisinin. *Antimicrob Agents Chemother.*, 2010, 54, 966-967.
84. **Pradines B**, Pistone T, Ezzedine K, Briolant S, Bertaux L, Receveur MC, Parzy D, Millet P, Rogier C, Malvy D. Quinine-resistant Plasmodium falciparum malaria in traveler, France, 2007. *Emerg Infect Dis.*, 2010, 16, 546-548.
85. Resseguier N, Machault V, Ollivier L, Orlandi-Pradines E, Texier G, **Pradines B**, Gaudard J, Buguet A, Tourette-Turgis C, Rogier C. Determinants of compliance with malaria chemoprophylaxis among French soldiers during mission in inter-tropical Africa. *Malar J.*, 2010, 9, 41.

86. Wenzel NI, Chavain N, Wang Y, Friebolin W, Maes L, **Pradines B**, Lanzer M, Yardley V, Brun R, Herold-Mende C, Biot C, Toth ., Davioud-Charvet E. Antimalarial versus cytotoxic properties of dual drugs derivated from 4-aminoquinolines and Mannich bases: interaction with DNA. *J Med Chem.*, 2010, 53, 3214-3226.
87. Wurtz N, Briolant S, Gil M, Parquet V, Henry M, Baret E, Amalvict R, Almeras L, Rogier C, **Pradines B**. Synergy of mefloquine activity by atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the Pfmdr1 gene. *J Antimicrob Chemother.*, 2010, 65, 1387-1394.
88. Briolant S, Almeras L, Belghazi M, Boucoment-Chapeaublanc E, Wurtz N, Fontaine A, Granjeaud N, Fusai T, Rogier C, **Pradines B**. Plasmodium falciparum proteome changes in response to doxycycline treatment. *Malar J.*, 2010, 9, e141.
89. Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, **Pradines B**. Atorvastatin as a potential anti-malarial drug: in vitro synergy in combination therapy with quinine against Plasmodium falciparum. *Malar J.*, 2010, 9, e139.
90. Briolant S, Henry M, Ouevray C, Amalvict R, Baret E, Didillon E, Rogier C, **Pradines B**. Absence of association between piperazine in vitro responses and polymorphisms in the genes pfcr1, pfmdr1, pfmrp and pfnhe in Plasmodium falciparum. *Antimicrob Agents Chemother.*, 2010, 54, 3537-3544.
91. Rebaudet S, Bogreau H, Silai R, Lepere JF, Bertaux L, **Pradines B**, Delmont J, Gautret P, Parola P, Rogier C. Genetic structure of Plasmodium falciparum and elimination of malaria, Comoros Archipelago. *Emerg Infect Dis.*, 2010, 16, 1686-1694.
92. Arabicia R, Dubar F, **Pradines B**, Forfar I, Dive D, Klahn H, Biot C. Synthesis and antimalarial activities of rhenium bioorganometallics based on the 4-aminoquinoline structure. *Bioorg Med Chem.*, 2010, 18,8085-8091.
93. Mourou R, Coffinet T, Jarjaval F, **Pradines B**, Amalvict R, Rogier C, Kombila M, Pages F. Malaria transmission and insecticide resistance of Anopheles gambiae s. l. in Libreville and Port-Gentil, Gabon. *Malar J.*, 2010, 9, 321.
94. **Pradines B**, Briolant S, Henry M, Ouevray C, Baret E, Amalvict R, Didillon E, Rogier C. Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. *Malar J.*, 2010, 9, 339.
95. Dia A, De Laval F, **Pradines B**, Deparis X. Plasmodium knowlesi. Y penser devant tout accès palustre de retour d'Asie du Sud-Est. *Le concours Médical*, 2010, 132, 382.
96. **Pradines B**, Dormoi J, Briolant S, Bogreau H, Rogier C. La résistance aux antipaludiques. *Rev Fr Lab.*, 2010, 422, 51-62.
97. Alibert-Franco S, **Pradines B**, Mahamoud A, Davin-Regli A, Pages JM. Efflux mechanism, a new target to combat multidrug resistant pathogen. *Current Med. Chem.*, 2009, 16, 301-317.
98. Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, Hovette P, Mabika Mamfoumbi M, Koeck JL, Delmont J, Spiegel A, Gardair JP, Trape JF, Kombila M, Minodier P, Fusai T, Rogier C, **Pradines B**. A multi-normal distribution model suitable for the distribution of Plasmodium falciparum in vitro chemosusceptibility to doxycycline. *Antimicrob Agents Chemother.*, 2009, 53, 688-695.
99. Biot C, Chavain N, Dubar F, **Pradines B**, Trivelli X, Brocard J, Forfar I, Dive D. Structure-activity relationships of 4-N-substituted ferroquine analogues. Time to re-evaluate the mechanism of action of ferroquine. *J Organomet Chem.*, 2009, 694, 545-854.
100. Almeras L, Orlandi-Pradines E, Fontaine A, Villard C, Boucomont E, Denis De Seneville L, Baragatti M, Pascual A, **Pradines B**, Corre-Catelin N, Pages F, Reiter P, Rogier C, Fusai T. Sialome singulay between Aedes aegypti colonies. *Vector-Borne Zoonot Dis.*, 2009, 9, 531-541.
101. Salmi C, Loncle C, Vidal N, Ogier C, Letourneux Y, **Pradines B**, Brunel JM. 3-aminosterol compounds as a new class of antimalarial agents against chloroquine-susceptible and -resistant Plasmodium falciparum. *Lett Drug Design Discov.*, 2009, 6, 163-166.
102. Henry M, Briolant S, Zettor A, Pelleau S, Baragatti M, Baret E, Mosnier J, Amalvict R, C, **Pradines B**, Fusai T, Rogier. Plasmodium falciparum Na<sup>+</sup>/H<sup>+</sup> exchanger 1 transporter is involved in reduced susceptibility to quinine. *Antimicrob Agents Chemother.*, 2009, 53, 1926-1930.
103. Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusai T, Rogier C, **Pradines B**. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. *Antimicrob Agents Chemother.*, 2009, 53, 2248-2252.
104. Pomares-Estrans C, Delaunay P, Mottard A, Cua E, Roger PM, **Pradines B**, Parzy D, Bogreau H, Rogier C, Jeannin C, Karch S, Fontenille D, Dejour Salamanca D, Legros F, Marty P. Conjugal autochthonous airport malaria from Paris to French Riviera (France). *Malar J.*, 2009, 8, 202.
105. Briolant S, Wurtz N, Zettor A, Rogier C, **Pradines B**. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphism and pftetQ and pfmdt copy numbers. *J Infect Dis.*, 2010, 201, 153-159.
106. Almeras L, Fontaine A, Belghazi M, Bourdon S, Boucomont-Chapeaublanc E, Orlandi-Pradines E, Baragatti M, Corre-Catelin N, Reiter P, **Pradines B**, Fusai T, Rogier C. Salivary gland protein repertoire from Aedes aegypti mosquitoes. *Vector-Borne Zoonot Dis.*, 2010, 10, 391-402.
107. Guetzoyan L, Yu, XM, Ramiandrasoa F, Pethe S, Rogier C, **Pradines B**, Cresteil T, Martine Perrée-Fauvet M, Mahy JP. Antimalarial acridines: Synthesis, in vitro activity against P. falciparum and interaction with hemozoin. *Bioorg Med Chem.*, 2009, 17, 8032-8039.
108. Dubar F, Anquetin G, **Pradines B**, Khalife J, Dive D, Biot C. Antimalarial activity enhancement of ciprofloxacin by using a double prodrug/bioorganometallic approach. *J Med Chem.*, 2009, 52, 7954-7957

109. Queyriaux B, **Pradines B**, Hasseine L, Coste S, Rodriguez P, Coffinet T, Haus-Cheymol R, Rogier C. Quand le paludisme prend l'avion pour la France : une mise au point sur le paludisme d'aéroport et sa prévention. *Presse Med.*, 2009, 38,1106-1109.
110. Eboumbou Mokokoko C, Bogreau H, Briolant S, **Pradines B**, Rogier C. Distinguer les populations de *Plasmodium falciparum* en recherche clinique. *Med Trop.*, 2009, 69, 613-617.
111. Eboumbou Mokokoko C, Bogreau H, Briolant S, **Pradines B**, Rogier C. Marqueurs moléculaires des résistances de *Plasmodium falciparum* aux antipaludiques. *Med Trop.*, 2009, 69, 606-612.
112. Henry M, Alibert S, Rogier C, Barbe J, **Pradines B**. Inhibition of efflux of quinolines as new therapeutic strategy in malaria. *Current Topics Med Chem.*, 2008, 8, 563-578.
113. Savini H, Bogreau H, Bertaux L, Bouchiba H, Kraemer P, Parzy D, Garnotel E, Rogier C, Simon F, **Pradines B**. First case of emergence of atovaquone-proguanil resistance in *Plasmodium falciparum* during treatment in a traveller in Comoros. *Antimicrob Agents Chemother.*, 2008, 52, 2283-2284.
114. Machault V, Orlandi-Pradines E, Michel R, Pages F, Texier G, **Pradines B**, Fusai T, Boutin JP, Rogier C. Remote sensing and malaria risk for travelers to Africa. *J Travel Med.*, 2008, 15, 216-220.
115. Henry M, Briolant S, Fontaine A, Mosnier J, Baret E, Amalvict R, Fusai T, Fraisse L, Rogier C, **Pradines B**. In vitro activity of ferroquine is independent of polymorphisms in transport proteins genes implicated in quinoline resistance in *Plasmodium falciparum*. *Antimicrob Agents Chemother.*, 2008, 52, 2755-2759.
116. Henry M, Alibert S, Baragatti M, Mosnier J, Baret E, Amalvict R, Legrand E, Fusai T, Barbe J, Rogier C, Pagès JM., **Pradines B**. Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in *Plasmodium falciparum* malaria. *Med Chem.*, 2008, 4, 426-437.
117. Briolant S, Fusai T, Rogier C, **Pradines B**. Tetracycline antibiotics in malaria. *Open Trop Med. J.*, 2008, 1, 41-56.
118. Gardella F, Assi S, Simon F, Bogreau H, Eggelte T, Ba F, Foumane V, Henry M.C, Basco L, Trape JF, Lalou R, Martelloni M, Desbordes M, Baragatti M, Briolant S, Almeras L, **Pradines B**, Fusai T, Rogier C. Antimalarial drug use in general populations of tropical Africa. *Malar J.*, 2008, 7, 124.
119. Pages F, Texier G, **Pradines B**, Gadiaga L, Machault V, Jarjaval F, Penhoat K, Berger F, Rogier C, Sokhna C. Malaria transmission in Dakar: a two-year survey. *Malar J.*, 2008, 7, 178.
120. Oliver M, Simon F, De Monbrison F, Beavogui AH, **Pradines B**, Ragot C, Moalic JL, Rapp C, Picot S. Le nouvel âge de la primaquine contre le paludisme. *Med Mal Infect.*, 2008, 38, 169-179.
121. Migliani R, Ollivier L, Romand O, Verret C, Haus-Cheymol R, Todesco A, Pages F, **Pradines B**, Queyriaux B, Texier G, Michel R, Spiegel A, Boutin JP. Paludisme chez les militaires français en Côte d'Ivoire de 1998 à 2006. *BEH.*, 2008, 23-24, 209-212.
122. Biot C, **Pradines B**. Petit précis des médicaments antipaludiques. *Biofutur*, 2008, 293, 38-41.
123. Norate N, Durand R, Tall A, Marrama L, Sohna C, **Pradines B**, Cojean S, Guillotte M, Bischoff E, Ekala MT, Bouchier C, Fandeur T, Ariey F, Patarapotikul J, Le Bras J, Trape JF, Rogier C, Mercereau-Puijalon O. Rapid dissemination of *Plasmodium falciparum* drug resistance despite strictly controlled antimalarial use. *Plos One*, 2007, 1, e139.
124. Guetzoyan L, Ramiandrasoa F, Dorizon F, Desprez C, Bridoux A, Rogier C, **Pradines B**, Peree-Fauvet M. In vitro efficiency of new acridyl derivatives against *Plasmodium falciparum*. *Bioorg Med Chem.*, 2007, 15, 3278-3289.
125. Briolant S, Parola P, Fusai T, Madamet-Torrentino M, Baret E, Mosnier J, Delmont J, Parzy D, Minodier P, Rogier C., **Pradines B**. Influence of oxygen on asexual blood cycle and susceptibility of *Plasmodium falciparum* to chloroquine : requirement of standardized in vitro assay. *Malar J.*, 2007, 6:44.
126. **Pradines B**, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, Mosnier J, Briolant S, Fusai T, Rogier C. Atovarstatin is ten-fold more active than other statins against *Plasmodium falciparum* parasites. *Antimicrob Agents Chemother.*, 2007, 51, 2654-2655.
127. Coffinet T, Mourou JR, **Pradines B**, Toto JC, Jarjaval F, Amalvict R, Kombila M, Carnevale P, Pagès F. First record of *Aedes albopictus* (Skuse) from Gabon. *J Am Mosquito Contr Assoc.*, 2007, 23, 471-472.
128. Parola P, **Pradines B**, Simon F, Carlotti MP, Minodier P, Ranjeva MP, Badiaga S, Delmont J, Morillon M, Silai S, Brouqui P, Parzy D. Antimalarial drug susceptibility and point mutations associated with *Plasmodium falciparum* drug resistance of 248 isolates imported from Comoros to Marseille, France in 2004-2006. *Am J Trop Med Hyg.*, 2007, 77, 431-437.
129. Orlandi-Pradines E, Almeras L, Denis De Senneville L, Barbe S, Remoue F, Villard C, Cornélie S, Penhoat K, Pascual A, Bourgouin C, Fontenille D, Bonnet J, Corre-Catelin N, Reiter P, Pages F, Laffite D, Boulanger D, Simondon F, **Pradines B**, Fusai T, Rogier C. Antibody response against saliva antigens of *Anopheles gambiae* and *Aedes aegyptii* in travellers in tropical Africa. *Microbes Infect.*, 2007, 9, 1454-1462.
130. Biot C, **Pradines B**, Sergeant MH, Gut J, Rosenthal PJ, Chibale K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. *Bioorg Med Chem Lett.*, 2007, 17, 6434-6438.
131. **PRADINES B**. Une résistance transitoire. *La Recherche*, 2007, 404, 23.
132. Briolant S, Almeras L, Fusai T, Rogier C, **Pradines B**. Cyclines et paludisme. *Med Trop.*, 2007, 67, 86-96.
133. Almeras L, Briolant S, Orlandi-Pradines E, Fontaine A, Henry M, Bogreau H, **Pradines B**, Rogier C, Fusai T. Analyses protéomiques et parasitoses : principes et applications. *Med Trop.*, 2007, 67, 188-196.



134. Musset L, **Pradines B**, Parzy D, Durand R, Bigot P, Le Bras J. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum from untreated French travellers. *J Antimicrob Chemother.*, 2006, 57, 110-115.
135. Daher W, Biot C, Fandeur T, Jouin H, Pelinski L, Viscogliosi E, Fraisse L, **Pradines B**, Brocard J, Khalife J, Dive D. Assessment of P. falciparum resistance to ferroquine in field isolates and in W2 strain under pressure. *Malar J.*, 2006, 5:11.
136. Henry M, Alibert S, Orlandi-Pradines E, Bogreau H, Fusai T, Rogier C, Barbe J, **Pradines B**. Chloroquine resistance reversal agents as antimalarial drugs. *Curr Drug Targets*, 2006, 7, 935-948.
137. Bogreau H, Renaud R, Bouchiba H, Durand P, Assi SB, Henry M-C, Garnotel E, **Pradines B**, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Puijalon O, Rogier C. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. *Am J Trop Med Hyg.*, 2006, 74, 953-959.
138. Henry M, Bordes J, Diallo I, **Pradines B**, Ka S, Diatta B, Wade B, M'Baye PS, Sane M, Thiam M, Gueye PM, Touze JE, Debonne JM, Rogier C, Fusai T. Urban malaria at Dakar, Senegal : Chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. *Am J Trop Med Hyg.*, 2006, 75, 146-151.
139. **Pradines B**, Tall A, Ramiandrasoa F, Spiegel A, Fusai T, Mosnier J, Daries W, Trape JF, Kunesch G, Parzy D, Rogier C. Compounds with iron chelating effects for treatment of Plasmodium falciparum infections. In vitro activity against Senegalese isolates and comparison with standard antimalarial drugs. *J Antimicrob Chemother.*, 2006, 57, 1093-1099.
140. Orlandi-Pradines E, Penhoat K, Durand C, Pons C, Bay C, **Pradines B**, Fusai T, Josse R, Dubrous P, Meynard JB, Durand JP, Druihle R, Boutin JP, Rogier C. Exposure to malaria transmission of troops in operation in tropical Africa and efficacy of individual protective devices against malaria vectors. *Am J Trop Med Hyg.*, 2006, 74, 979-985.
141. Biot C, Daher W, Ndiaye C, Melnyck P, **Pradines B**, Chavain N, Pellet A, Fraisse L, Pelinsky L, Jarry C, Brocard J, Khalife J, Forbar-Bares I, Dive D. Probing the role of the covalent linkage of ferrocene into a chloroquine template. *J Med Chem.*, 2006, 49, 4707-4714.
142. **Pradines B**, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, Mosnier J, Callec A, Cren J, Amalvict R, Gardair JP, Rogier C. Prevalence of the in vitro resistance to eleven standard or new antimalarial drugs against Plasmodium falciparum isolates from Pointe-Noire, Republic of Congo. *J Clin Microbiol.*, 2006, 44, 2404-2408.
143. **Pradines B**, Mabika Mamfoumbi M, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal and Djibouti. *Antimicrob Agents Chemother.*, 2006, 50, 3225-3226.
144. D'ortenzio E, Godineau N, Lusina D, Fenneteau O, Parola P, Durand R, Morillon M, Galeazzi G, Debord T, Bigel ML, Hurst JP, Houzé P, Hubert V, Carlotti MP, Houzé S, **Pradines B**, Parzy D, Le Bras J. Paludisme importé en France en 2005 dans 11 hôpitaux de France métropolitaine : prophylaxie, chimiorésistance et efficacité thérapeutique. *BEH.*, 2006, 32, 240-242.
145. Rogier C, Orlandi-Pradines E, Fusai T, **Pradines B**, Briolant S, Almeras L. Vaccins contre le paludisme : perspectives et réalités. *Med Mal Inf.*, 2006, 36, 414-422.
146. Rogier C, **Pradines B**, Bogreau H, Koeck JL, Kamil M, Puijalon O. Epidemic malaria and spread of the resistance of Plasmodium falciparum to antimalarial drugs in the city of Djibouti. *Emerg Infect Dis.*, 2005, 11, 317-321.
147. **Pradines B**, Ramiandrasoa F, Fusai T, Hammadi A, Henry M, Briolant S, Orlandi-Pradines E, Bogreau H, Mosnier J, Daries W, Kunesch G, Le Bras J, Rogier C. Generation of free radicals and enhancement of hemin-induced membrane damage by a catechol iron chelator in Plasmodium falciparum. *J Biol Sci.*, 2005, 5, 463-471.
148. **Pradines B**, Pages JM, Barbe J. Chemosensitizers in drug transport mechanisms involved in protozoan resistance. *Curr Drug Targets - Infect. Disorders*, 2005, 5, 411-431.
149. **Pradines B**, Orlandi-Pradines E, Henry M, Bogreau H, Fusai T, Mosnier J, Baret E, Durand C, Bouchiba H, Penhoat K, Rogier C. Métalloènes et paludisme : une nouvelle approche thérapeutique. *Ann Pharm Fr.*, 2005, 63, 284-294.
150. Boutin JP, **Pradines B**, Pages F, Legros F, Rogier C, Migliani R. Epidémiologie du paludisme. *Rev Prat.*, 2005, 55, 841-848.
151. Le Bras J, **Pradines B**, Durand R, Parzy D. La prescription de l'association chloroquine-proguanil (Savarine) est-elle toujours justifiée pour la prévention du paludisme en zone 2 ? *Rev Prat.*, 2005, 55, 856-857.
152. D'ortenzio E, Durand R, **Pradines B**, Parzy D, Le Bras J. Evolution de la chimiosensibilité du paludisme d'importation en 2003-2004. *BEH.*, 2005, 24-25, 127-128.
153. Rogier C, Fusai T, **Pradines B**, Trape JF. Comment évaluer la morbidité attribuable au paludisme en zone d'endémie ? *Rev Epidemiol Sante Publique*, 2005, 53, 299-309.
154. Parola P, **Pradines B**, Gazin P, Keundjian A, Silai R, Parzy D. Chimiosensibilité de Plasmodium falciparum importé des Comores à Marseille en 2001-2003. *Med Mal Inf.*, 2005, 35, 489-491.
155. Grellepois F, Chorki F, Ourevitch M, Charneau S, Grellier P, McIntosh KA, Charman WN, **Pradines B**, Crousse B, Bonnet-Delpon D, Begue JP. Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin. *J Med Chem.*, 2004, 47, 1423-1433.
156. Parola P, Gazin P, **Pradines B**, Parzy D, Delmont J, Brouqui P. Marseilles: a surveillance site for malaria from Comoros Islands. *J Trav Med.*, 2004, 11, 184-186.

157. Millet J, Torrentino-Madamet M, Alibert S, Rogier C, Santelli-Rouvier C, Mosnier J, Baret E, Barbe J, Parzy D, **Pradines B**. Dihydroethanoanthracene derivatives as in vitro malarial chloroquine resistance reversal agents. *Antimicrob Agents Chemother.*, 2004, 48, 2753-2756.
158. Santelli-Rouvier C, **Pradines B**, Berthelot M, Parzy D, Barbe J. Arylsulfonyl acridinyl derivatives : activity on *Plasmodium falciparum*. *Eur J Med Chem.*, 2004, 39, 735-744.
159. Millet J, Alibert S, Torrentino-Madamet M, Rogier C, Santelli-Rouvier C, Bigot P, Mosnier J, Baret E, Barbe J, Parzy D, **Pradines B**. Polymorphisms in *Plasmodium falciparum* drug transporter proteins and reversal of in vitro chloroquine resistance by a 9,10-dihydroethanoanthracene derivative. *Antimicrob Agents Chemother.*, 2004, 48, 4869-4872.
160. Ralaimazava P, **Pradines B**, Keundjian A, Durand R, Le Bras J. Chimiosensibilité du paludisme importé en France en 2001 et 2002. *BEH.*, 2004, 6, 21-24.
161. Pouvelle B, Traore B, Nogueira PA, **Pradines B**, Lepolard C, Gysin J. Modeling of *Plasmodium falciparum*-infected erythrocyte cytoadhesion in microvascular conditions: chondroitin-4-sulfate binding, a competitive phenotype. *J Infect Dis.*, 2003, 187, 292-302.
162. Hammadi A, Ramiandrasoa F, Sinou V, Rogier C, Fusai T, Le Bras J, Parzy D, Kunesch G, **Pradines B**. Cellular uptake of a catechol iron chelator and chloroquine into *Plasmodium falciparum* infected erythrocytes. *Biochem Pharmacol.*, 2003, 65, 1351-1360.
163. Debouzy JC, Gadelle A, Pailler JY, Fusai T, Dabouis V, **Pradines B**, Fauvelle F, Crouzier D. In vitro cellular toxicity and in vivo lethality studies of alkylated  $\alpha$ -anhydro cyclodextrins. *STP. Pharma Sciences*, 2003, 13, 209-214.
164. Le Bras J, **Pradines B**. Chemoresistance in *falciparum* malaria. *Trends Parasitol.*, 2003, 19, 435-436.
165. **Pradines B**, Vial H, Olliaro P. Prophylaxie et traitement du paludisme: problèmes, récents développements et perspectives. *Med Trop.*, 2003, 63, 79-98.
166. **Pradines B**, Millet J, Henry M. Chélation du fer dans la thérapie antipaludique. *Med Trop.*, 2003, 63, 119-130.
167. **Pradines B**, Ramiandrasoa F, Rolain JM, Rogier C, Mosnier J, Daries W, Fusai T, Kunesch G, Le Bras J, Parzy D. In vitro potentiation of antibiotics activities by a catechol siderophore against *Plasmodium falciparum* chloroquine resistant parasites. *Antimicrob Agents Chemother.*, 2002, 46, 225-228.
168. **Pradines B**, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T, Millet P, Panconi E, Trape JF, Parzy D. In vitro activities of Ferrochloroquine against 55 Senegalese isolates of *Plasmodium falciparum* in comparison with those of standard antimalarial drugs. *Trop Med Int Health*, 2002, 7, 265-270.
169. **Pradines B**, Alibert-Franco S, Houdoin C, Mosnier J, Santelli-Rouvier C, Papa V, Rogier C, Fusai T, Barbe J, Parzy D. In vitro reversal of chloroquine resistance in *Plasmodium falciparum* with dihydroethanoanthracene derivatives. *Am J Trop Med Hyg.*, 2002, 66, 661-666.
170. **Pradines B**, Alibert S, Houdoin C, Santelli-Rouvier C, Mosnier J, Fusai T, Rogier C, Barbe J, Parzy D. In vitro increase of chloroquine accumulation induced by dihydroethano- and etheno- anthracenes derivatives in *Plasmodium falciparum* parasitized erythrocytes. *Antimicrob Agents Chemother.*, 2002, 46, 2061-2068.
171. **Pradines B**, Rolain JM, Ramiandrasoa F, Fusai T, Mosnier J, Rogier C, Daries W, Baret E, Kunesch G, Le Bras J, Parzy D. Iron chelators as antimalarial agents: in vitro activity of di-catecholate against *Plasmodium falciparum*. *J Antimicrob Chemother.*, 2002, 50, 177-187.
172. Alibert S, Santelli-Rouvier C, **Pradines B**, Houdoin C, Parzy D, Karolak-Wojciechowska, Barbe J. Synthesis and effects on chloroquine susceptibility in *Plasmodium falciparum* of a series of new dihydroanthracene derivatives. *J Med Chem.*, 2002, 45, 3195-3209.
173. Ralaimazava P, Durand R, Godineau N, Keundjian A, Jezic Z, **Pradines B**, Bouchaud O, Le Bras J. Profile and evolution of the chemosusceptibility of *falciparum* malaria imported into France in 2000. *Euro Surveill.*, 2002, 7, 113-118.
174. Diouf B, **Pradines B**, Spiegel A, Trape JF, Dieye A, Parzy D, Garraud O, Perraut R. Réévaluation des tests d'inhibition de culture et de réinvasion parasitaire de *P. falciparum* pour mesurer un degré de prémunition chez des individus vivant en zone d'endémie. *Dak Med.*, 2002, 47, 5-11.
175. **Pradines B**, Fusai T, Rogier C, Sinou V, Millet J, Henry M, Parzy D. Progress in the development of antimalarial drugs: iron chelation and reversal chloroquine resistance as therapy for malaria. *Recent Res Devel Antimicrob Agents & Chemother.*, 2002, 5, 24-43.
176. Gari-Toussaint M, **Pradines B**, Mondain V, Keundjian A, Dellamonica P, Le Fichoux Y. Sénégal et paludisme. Echec prophylactique vrai de la méfloquine. *Presse Med.*, 2002, 31, 1136.
177. Ralaimazava P, Durand R, Godineau N, Keundjian A, Jezic Z, **Pradines B**, Bouchaud O, Le Bras J. Profil et évaluation de la chimiosensibilité du paludisme d'importation à *Plasmodium falciparum* en France, 2000. *BEH.*, 2002, 26, 127-129.
178. Touze JE, Fourcade L, **Pradines B**, Hovette P, Paule P, Heno P. Les modes d'action des antipaludiques. Intérêt de l'association atovaquone-proguanil. *Med Trop.*, 2002, 62, 219-224.
179. Parzy D, Keundjian A, Fusai T, Rogier C, Sinou V, **Pradines B**. La recherche en parasitologie au service des forces : le paludisme. *Médecine et Armées*, 2002, 30, 487-493.
180. **Pradines B**, Rogier C, Fusai T, Mosnier J, Daries W, Baret E, Parzy D. In vitro activities of antibiotics against *Plasmodium falciparum* are inhibited by iron. *Antimicrob Agents Chemother.*, 2001, 45, 1746-1750.
181. **Pradines B**, Fusai T, Daries W, Laloge V, Rogier C, Millet P, Panconi E, Kombila M, Parzy D. Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of *Plasmodium falciparum*. *J Antimicrob Chemother.*, 2001, 48, 179-184.

182. **Pradines B**, Fusai T, Rogier C, Keundjian A, Sinou V, Merckx A, Mosnier J, Daries W, Torrentino M, Parzy D. Recherche actuelle sur les Apicomplexa . Prophylaxie et traitement du paludisme : évaluation in vitro de nouveaux composés. *Ann Pharm Fr.*, 2001, 59, 319-323.
183. Parzy D, Rogier C, Keundjian A, Fusai T, **Pradines B**, Sinou V. Recherches sur le paludisme à l'IMTSSA- le Pharo. *Med Trop.*, 2001, 61, 11-14.
184. **Pradines B**, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, Trape JF, Parzy D. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. *Am J Trop Med Hyg.*, 2000, 62, 82-85.
185. **Pradines B**, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M. In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. *Am J Trop Med Hyg.*, 1999, 60, 105-108.
186. **Pradines B**, Tall A, Fusai T, Spiegel A, Hienne R, Rogier C, Trape JF, Parzy D. In vitro activity of benflumetol against 158 African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. *Antimicrob Agents Chemother.*, 1999, 43, 418-420.
187. Alibert-Franco S, Santelli-Rouvier C, Barbe J, **Pradines B**, Houdoin C, Parzy D. 9,10-(3',4'-pyrrolino)-9,10-dihydroanthracene and structurally related compounds as synergistic antimalarial drugs. *Heterocyclic Commun.*, 1999, 5, 235-240.
188. **Pradines B**, Mabika Mamfoumbi M, Keundjian A, Lebeau C, Fusai T, Owono Medang M, Rogier C, Parzy D, Kombila M. Sensibilité in vitro d'isolats Gabonais de Plasmodium falciparum vis à vis de la chloroquine et du cycloguanil. *Bull Soc Path Exot.*, 1999, 92, 91-94.
189. Parzy D, Rogier C, **Pradines B**, Keundjian A, Fusai T, Bigot P, Carme E. Apport de la biologie moléculaire dans le diagnostic de résistance de Plasmodium falciparum aux antipaludiques. *Rev Fr Lab.*, 1999, 315, 31-36.
190. **Pradines B**, Rogier C, Fusai T, Tall A, Trape JF, Doury J.C. In vitro activity of artemether against african isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. *Am J Trop Med Hyg.*, 1998, 58, 354-357.
191. **Pradines B**, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, Trape JF, Doury J.C. In vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. *J Antimicrob Chemother.*, 1998, 42, 333-339.
192. **Pradines B**, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M. In vitro susceptibility of Gabonese isolates of Plasmodium falciparum to artemether, and comparison with chloroquine, quinine, halofantrine and amodiaquine. *Parasitol.*, 1998, 117, 541-545.
193. Hienne R, Ricard G, Fusai T, Fujioka H, **Pradines B**, Aikawa M, Doury J.C. Plasmodium yoelii: Identification of rhoptry proteins using monoclonal antibodies. *Exp Parasitol.*, 1998, 90, 230-235.
194. Thanh Nga TT., Menage C, Begue JP, Bonnet-Delpon D, **Pradines B**, Doury JC, Dinh Thac T. Synthesis and antimalarial activity of fluoralkyl ethers of dihydroartemisinin. *J Med Chem.*, 1998, 41, 4101-4108.
195. Le Bras J, Durand R, Di Piazza JP, **Pradines B**, Longuet C, Parzy D. Prise en compte des disparités de résistance de Plasmodium falciparum en Afrique dans la décision chimioprophylactique. *Press Med.*, 1998, 27, 1419-1423.
196. Le Bras J, **Pradines B**, Di Piazza JP, Durand R, Godineau N, Bouchaud O, Roue R, Marchou B, Martet G, Longuet C, Parzy D. Résistance à la chloroquine et au cycloguanil de Plasmodium falciparum chez des patients arrivant en France après un voyage en Afrique sans chimioprophylaxie. *Bull Soc Path Exot.*, 1998, 91, 490-492.
197. Di Piazza JC, Durand R, Vaslin L, Keundjian A, Longuet C, **Pradines B**, Le Bras J. Chimiosensibilité du paludisme d'importation à Plasmodium falciparum en France en 1997. *BEH.*, 1998, 33, 141-142.
198. Parzy D, Doerig C, **Pradines B**, Rico A, Fusai A, Doury JC. Proguanil resistance in Plasmodium falciparum african isolates: assessment by mutation-specific PCR and in-vitro susceptibility testing. *Am J Trop Med Hyg.*, 1997, 57, 646-650.
199. Fusai T, Keundjian A, **Pradines B**, Parzy D, Doury JC. Evaluation de la chimiosensibilité de P. falciparum chez les militaires de 1991 à 1995. *Médecine et Armées*, 1997, 25, 29-32.
200. **Pradines B**, Ramiandrasoa F, Basco LK, Bricard L, Kunesch G, Le Bras J. In vitro activities of novel catecholate siderophores against Plasmodium falciparum. *Antimicrob Agent. Chemother.*, 1996, 40, 2094-2098.
201. Matias C, Mahamoud A, Barbe J, **Pradines B**, Doury JC. Synthesis and antimalarial activity of new 4,6-dialkoxy- and 4,6-bis(alkylthio)pyrido(3,2-g)quinoline derivatives. *Heterocycles*, 1996, 43, 1621-1632.
202. **Pradines B**, Rogier C, Fusai T, Tall A, Trape JF, Doury JC. Sensibilité in vitro de 85 isolats de Plasmodium falciparum au Sénégal. *Med Trop.*, 1996, 56, 141-145.
203. Parzy D, **Pradines B**, Keundjian A, Fusai T, Doury JC. Evaluation des résistances de Plasmodium falciparum aux antimalariques. *Med Trop.*, 1995, 55, 211-215.